ALXO

ALX Oncology Holdings Inc. (ALXO) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. ALX Oncology is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies. The company has no approved products and generates no product revenue. Its primary activities involve the clinical development of its lead candidate, evorpacept (a CD47 blocker), and its second candidate, ALX2004 (an EGFR-targeted antibody-drug conjugate).

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Capital Raise: In February 2026, the company completed a registered offering raising approximately $140.4 million in net proceeds. This included the issuance of ~77 million shares of common stock and pre-funded warrants for ~18.6 million shares.
• Expense Reduction: Total operating expenses decreased by 40% ($12.9 million) compared to Q1 2025.
  • R&D Expenses: Declined 43% to $13.6 million, driven by a reduction in workforce, fewer active clinical trials, and pipeline prioritization.
  • G&A Expenses: Declined 32% to $5.4 million, primarily due to lower personnel costs and reduced stock-based compensation following the workforce reduction in early 2025.
• Liquidity Position: Cash and investments increased from $48.3 million at year-end 2025 to $169.1 million at March 31, 2026, following the equity offering.
• Share Count: Outstanding shares increased from ~54.4 million (Dec 31, 2025) to ~134.5 million (March 31, 2026) due to the February offering.

Outlook, Risks, and Management Commentary

• Clinical Progress:
  • Evorpacept: The ASPEN-09-Breast trial (HER2+ breast cancer) was amended to a single-arm design based on CD47 expression and dosed its first patient in January 2026. The ASPEN-06 gastric cancer trial data showed significant benefit in patients with high CD47 expression.
  • ALX2004: The Phase 1 trial for this EGFR-targeted ADC began enrolling patients in the third dose cohort in January 2026 with no dose-limiting toxicities observed in the first two cohorts.
  • Program Pause: The ASPEN-CRC (colorectal cancer) study was paused in August 2025 to streamline resources.
• Liquidity Outlook: Management believes existing cash, investments, and the term loan facility will fund operations through the first half of 2028.
• Key Risks:
  • Capital Requirements: The company expects to continue incurring significant losses and will require substantial additional capital to complete clinical development and commercialization.
  • Regulatory Uncertainty: Success depends on FDA approval, which is uncertain. The company faces risks related to clinical trial outcomes and regulatory guidance changes.
  • Intellectual Property: Potential infringement claims from third parties (e.g., University Health Network patents regarding SIRPα) could limit market access in certain territories.
  • Stock Price Volatility: The company previously received a Nasdaq non-compliance notice regarding minimum bid price (resolved in September 2025) but faces ongoing risks of delisting if the price falls below $1.00.

Investor Verification Checklist

• Verify the runway estimate (first half of 2028) against current burn rates and potential inflation in clinical trial costs.
• Review the February 2026 Offering terms, specifically the exercise price and conditions of the pre-funded warrants issued to investors.
• Monitor the ASPEN-09-Breast trial enrollment and data readout timelines, as this is a critical near-term catalyst.
• Assess the status of the University Health Network patent litigation or licensing discussions regarding the SIRPα technology in the EU.
• Confirm compliance with Nasdaq listing requirements given the recent history of minimum bid price issues.